The current monoclonal antibodies that target secreted PCSK9 do not alter the levels of atherogenic very low-density lipoprotein cholesterol (VLDL-C) in plasma.36,37 Elevated levels of LDL-C and VLDL-C are indeed associated with an increased risk of ASCVD. The gene discussed is PCSK9; the disease is atherosclerosis.